康泰生物(300601) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 645,202,778.57, representing a 42.85% increase compared to CNY 451,659,438.75 in the same period last year[3] - Net profit attributable to shareholders decreased by 58.51% to CNY 22,434,088.56 from CNY 54,065,937.45 year-on-year[3] - The basic earnings per share decreased by 60.00% to CNY 0.02 from CNY 0.05 in the same period last year[3] - Net profit for the current period was ¥22,385,110.07, a decrease of 59% from ¥54,028,967.57 in the previous period[22] - The total comprehensive income for the current period was ¥22,328,228.76, down from ¥54,028,967.57, indicating a decrease of approximately 59%[23] Cash Flow - The net cash flow from operating activities improved by 39.22%, reaching CNY -46,303,417.98, compared to CNY -76,178,859.85 in the previous year[8] - Cash inflow from operating activities was ¥581,746,831.93, compared to ¥551,108,624.59 in the previous period, showing an increase of approximately 5.6%[25] - The net cash flow from investment activities was -65,225,875.91, compared to -377,609,311.64 previously[26] - Cash inflow from financing activities was 25,584,357.78, a decrease from 146,913,282.57 in the last period[26] - The net cash flow from financing activities was -98,941,780.52, contrasting with a positive 122,766,816.17 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 14,254,927,648.54, a decrease of 2.12% from CNY 14,563,714,495.33 at the end of the previous year[3] - The company reported a total liability of ¥4,571,533,462.31, down from ¥4,902,689,146.32 in the previous period, indicating a reduction of approximately 7%[21] - The company has a total of 8,025,395,103.09 in non-current assets, down from 8,321,425,556.94 at the beginning of the period, indicating a decrease of approximately 3.6%[18] - The company’s total liabilities and equity amounted to ¥14,254,927,648.54, a decrease from ¥14,563,714,495.33 in the previous period, representing a reduction of about 2.1%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 62,638[10] - The company reported a total of 231,096,718 shares under lock-up restrictions, with 154,050 shares newly added during the period[14] - The company has a total of 10 major shareholders, with the largest shareholder holding 201,730,680 shares, accounting for a significant portion of the total shares[11] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[12] Operating Costs and Expenses - The company reported a significant increase in operating costs, which rose by 137.99% to CNY 171,263,111.04, primarily due to increased sales volume[7] - Total operating costs amounted to ¥594,453,971.64, up 41% from ¥420,220,371.94 in the prior period[21] - Research and development expenses rose to ¥120,628,293.10, up from ¥107,609,673.57, marking a growth of about 12%[22] Other Financial Metrics - The company’s weighted average return on equity decreased to 0.23% from 0.56% year-on-year[3] - The company’s cash and cash equivalents decreased significantly from CNY 432,840,378.47 to CNY 219,937,690.38, representing a decline of about 49.3%[17] - Accounts receivable increased from CNY 2,787,045,936.42 to CNY 2,854,264,706.31, indicating a growth of approximately 2.4%[17] - Inventory decreased from CNY 782,767,957.21 to CNY 726,163,704.93, a reduction of about 7.2%[18] - Total current liabilities decreased from CNY 2,300,000,000 to CNY 2,200,000,000, reflecting a decrease of approximately 4.3%[17] Compliance and Regulations - The company disclosed that all major events as per the Securities Law and the Management Measures for Information Disclosure of Listed Companies have been reported in compliance with regulations[15] - The company did not undergo an audit for the first quarter report[27] - The new accounting standards will be implemented starting in 2025, but the company is not applicable for the current adjustments[28]